title: The effect of bevacizumab on the outcome of trabeculectomy with 5-Fluorouracil.
abstract: BACKGROUND
  To evaluate the effect of bevacizumab in trabeculectomies with 5-fluorouracil (5-FU).
  
  
  METHODS
  Thirty-six patients with uncontrolled glaucoma were included. Twelve patients underwent trabeculectomies with intracameral and subconjunctival injections of bevacizumab (1.25 mg/0.05 mL) and subconjunctival injections of 5-FU (5.0 mg/0.5 mL). The control group underwent trabeculectomies with subconjunctival injections of only 5-FU (5.0 mg/0.5 mL). The outcome measures, including best-corrected visual acuity, intraocular pressure (IOP), number of IOP-lowering medications, the assessment of bleb, and surgical complications, were evaluated until postoperative 24 months.
  
  
  RESULTS
  At each follow-up visit, there were no statistically significant differences between the 2 groups with regard to all outcome measures (P>0.05). The cumulative probabilities of surgical success were 50% and 58.33% in trabeculectomy with bevacizumab and 5-FU and in trabeculectomy with 5-FU, respectively (P=0.68, log-rank test).
  
  
  CONCLUSIONS
  Bevacizumab may not exert significant additive effects in trabeculectomy when administered in conjunction with 5-FU.
authors.affiliation: Department of Ophthalmology, Hallym University Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.
authors.forename: Wool
authors.initials: W
authors.lastname: Suh
authors.forename: Changwon
authors.initials: C
authors.lastname: Kee
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000068258:Bevacizumab; D016022:Case-Control Studies; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005901:Glaucoma / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D014130:Trabeculectomy; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000964:Antimetabolites, Antineoplastic; D000068258:Bevacizumab; D005472:Fluorouracil